131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial
Authors: CHARBONNEL BERNARD , ARODA VANITA R. , WESTERBACKA JUKKA , LAUAND FELIPE , BOELLE EMMANUELLE , CHENG ALICE Y. , ROSENSTOCK JULIO , BOLLI GEREMIA B. 
Published: June 2019

Diabetes prevalence in older people is increasing and older people have an increased risk of hypoglycemia. Results are shown here of subgroup analyses in adults aged ≥65 years (pre-planned) and ≥70 years (post hoc) of the BRIGHT study in insulin-naïve adults with T2DM.

Between treatment groups, baseline characteristics were similar; expected differences were observed between age subgroups: diabetes duration was longer, renal function was worse and BMI slightly lower in the ≥65 and ≥70 years groups vs. the overall population (Table).

HbA1c reductions from baseline to week 24 were similar between treatment groups in the overall and ≥65 years populations. Heterogeneity of treatment effect was seen across the &lt;/≥70 years subgroups (p=0.0087); HbA1c reduction in both treatment arms was similar in those &lt;70 years but greater with Gla-300 vs. IDeg-100 in those ≥70 years. Incidence and rates of hypoglycemia at week 24 were similar between treatment groups in all populations assessed. Insulin dose increase was slightly greater with Gla-300 vs. IDeg-100 in the overall and ≥65 years populations, but similar in both treatment groups in the ≥70 years subgroup.

Gla-300 provided similar HbA1c reduction vs. IDeg-100 in older people with T2DM, and greater reductions vs. IDeg-100 in those aged ≥70 years with no increased hypoglycemia risk in this frail population.

Disclosure

B. Charbonnel: Consultant; Self; AstraZeneca, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier. Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Takeda Pharmaceutical Company Limited. V.R. Aroda: Consultant; Self; ADOCIA, AstraZeneca, Becton, Dickinson and Company, Novo Nordisk Inc., Sanofi, Zafgen, Inc. Employee; Spouse/Partner; Merck & Co., Inc. Research Support; Self; AstraZeneca, Calibra Medical, Eisai Inc., Janssen Research & Development, Novo Nordisk Inc., Sanofi, Theracos, Inc. J. Westerbacka: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. F. Lauand: Employee; Self; Sanofi. E. Boelle: Employee; Self; Sanofi Research & Development. A.Y. Cheng: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, HLS Therapeutics, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; Boehringer Ingelheim International GmbH, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., mdBriefCase Group Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Melior Pharmaceuticals, Inc., Bukwang Pharm. Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc. Other Relationship; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. G.B. Bolli: Advisory Panel; Self; Sanofi. Research Support; Self; A. Menarini Diagnostics, Medtronic.

Funding

Sanofi (NCT02738151)